Adaptive therapy for early stage lung cancer with no MRD detected
Part of Cancer clinical trials.
This study tests a new approach for people with early-stage non-small cell lung cancer (NSCLC) who have had their tumor completely removed. It uses regular blood tests (MRD monitoring) to watch for any cancer cells left behind, so treatment can be given only if needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IA2, IB, or II non-small cell lung cancer (NSCLC) that was completely removed by surgery.
- Your blood tests (MRD) after surgery show no detectable cancer cells (two separate tests).
- Your doctor expects you to live at least 2 more years.
- You are in good physical condition (able to perform daily activities with little or no help, ECOG score 0 or 1).
- You agree to have a blood test for MRD every 3 months for 2 years after surgery.
- You have not had chemotherapy, radiation, or other cancer treatments before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This trial tests whether adding an extra interventional treatment after surgery helps for lung cancer that has a high chance of returning, as shown by a positive minimal residual disease (MRD) test. The goal is to see if this approach can reduce the risk of the cancer coming back.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This study tests a customized (“adaptive”) way to give radiation to the chest for newly diagnosed small cell lung cancer. It aims to improve how well treatment targets the tumor while safely adjusting to tumor changes during therapy.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.